advaxis
reports
third
quarter
ended
july
financial
results
provides
business
update
strategic
expansion
hot
program
nsclc
explore
potential
enhance
restore
sensitivity
checkpoint
inhibitors
enrolling
phase
study
efficacy
expansion
nsclc
based
sustained
durable
clinical
responses
first
two
three
evaluable
patients
part
b
combination
arm
enrolling
part
c
regimen
nsclc
patients
expression
patients
unfit
standard
care
combination
therapy
chemotherapy
princeton
globe
newswire
advaxis
nasdaq
adxs
biotechnology
company
focused
development
commercialization
immunotherapy
products
today
announced
update
clinical
pipeline
financial
results
third
quarter
ended
july
key
recent
corporate
clinical
pipeline
updates
presented
updated
clinical
data
ongoing
phase
trial
cell
lung
cancer
nsclc
demonstrating
durable
clinical
benefit
two
evaluable
patients
immediate
prior
progression
keytruda
including
one
durable
response
weeks
reduction
target
lesion
another
sustained
response
weeks
reduction
site
lesions
patients
remain
treatment
part
b
combination
arm
keytruda
clinical
benefit
achieved
immediate
prior
progression
keytruda
previous
best
responses
stable
disease
suggest
may
enhance
response
keytruda
including
one
durable
response
weeks
reduction
target
lesion
another
sustained
response
weeks
reduction
site
lesions
patients
remain
treatment
part
b
combination
arm
keytruda
initiated
part
b
combination
arm
efficacy
expansion
enroll
patients
evaluate
potential
combination
keytruda
restore
enhance
responsiveness
checkpoint
inhibitors
refractory
nsclc
patients
restore
enhance
responsiveness
checkpoint
inhibitors
refractory
nsclc
patients
initiated
part
c
combination
arm
evaluate
combination
keytruda
first
line
treatment
patients
nsclc
expression
unfit
chemotherapy
first
line
treatment
patients
nsclc
expression
unfit
chemotherapy
monotherapy
combination
keytruda
appeared
safe
well
tolerated
dose
limiting
toxicities
added
toxicity
combination
setting
appeared
safe
well
tolerated
dose
limiting
toxicities
added
toxicity
combination
setting
announced
common
stock
purchase
agreement
million
lincoln
park
capital
management
commentary
highly
encouraged
clinical
biomarker
data
ongoing
phase
study
nsclc
continued
execute
expansion
evaluation
potential
synergistically
enhance
restore
sensitivity
checkpoint
inhibitors
said
kenneth
berlin
president
chief
executive
officer
advaxis
quarter
begun
enrollment
expansion
part
b
evaluate
promising
signals
sustained
clinical
benefit
observed
first
dose
cohort
part
b
nsclc
patients
immediate
prior
progression
could
yet
another
strategy
rechallenge
tumor
checkpoint
inhibitor
without
stop
drug
progression
addition
started
enrollment
part
c
evaluate
combination
moving
hot
program
first
line
treatment
patients
metastatic
nsclc
would
receive
alone
per
label
indication
expression
patients
unfit
receive
standard
care
regimen
combination
platinum
believe
two
clinical
evaluations
part
b
part
c
study
elucidate
potential
improve
responses
checkpoint
inhibitors
diverse
clinical
settings
patients
limited
treatment
options
anticipate
additional
data
program
end
berlin
continued
particularly
encouraged
safety
tolerability
profile
monotherapy
combination
dose
limiting
toxicities
observed
believe
important
addition
standard
care
patients
whose
illness
makes
ineligible
forms
chemotherapy
recently
announced
common
stock
purchase
agreement
allows
us
continue
prioritization
hot
program
ongoing
expansions
nsclc
well
initiation
phase
study
prostate
cancer
patients
biochemical
recurrence
year
third
quarter
ended
july
financial
results
research
development
expenses
third
quarter
fiscal
year
million
compared
million
third
quarter
fiscal
year
decrease
largely
attributable
winding
phase
phase
studies
announced
june
october
respectively
general
administrative
expenses
three
months
ended
july
approximately
million
compared
million
period
decrease
expenses
mainly
attributable
lower
legal
fees
business
development
costs
july
company
approximately
million
cash
cash
equivalents
company
believes
sufficient
capital
fund
obligations
become
due
ordinary
course
business
july
advaxis
advaxis
biotechnology
company
focused
development
commercialization
proprietary
antigen
delivery
products
immunotherapies
based
platform
technology
utilizes
live
attenuated
listeria
monocytogenes
lm
bioengineered
secrete
antigen
adjuvant
fusion
proteins
strains
believed
significant
advancement
immunotherapy
integrate
multiple
functions
single
immunotherapy
designed
access
direct
antigen
presenting
cells
stimulate
cell
immunity
activate
immune
system
equivalent
multiple
adjuvants
simultaneously
reduce
tumor
protection
tumor
microenvironment
enable
cells
eliminate
tumors
learn
advaxis
visit
connect
twitter
linkedin
facebook
youtube
statements
press
release
contains
statements
made
pursuant
safe
harbor
provisions
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
statements
express
current
beliefs
expectations
management
including
limited
statements
related
expected
clinical
development
company
drug
product
candidates
risks
discussed
company
filings
sec
including
without
limitation
annual
report
form
filed
december
form
february
periodic
reports
form
form
statements
contained
herein
describe
historical
facts
statements
subject
risks
uncertainties
could
cause
actual
results
performance
achievements
differ
materially
discussed
statements
company
cautions
readers
place
undue
reliance
statements
speak
date
made
company
undertakes
obligation
update
revise
statements
except
otherwise
required
law
whether
result
new
information
future
events
otherwise
registered
trademark
merck
sharp
dohme
subsidiary
merck
kenilworth
usa
advaxis
inc
selected
balance
sheet
data
thousands
july
october
unaudited
cash
cash
equivalents
total
assets
total
stockholders
equity
statements
operations
unaudited
thousands
except
share
per
share
data
three
months
ended
july
nine
months
ended
july
revenue
operating
expenses
research
development
expenses
general
administrative
expenses
total
operating
expenses
loss
operations
income
net
loss
benefit
income
taxes
income
tax
expense
net
loss
net
loss
per
common
share
basic
diluted
weighted
average
number
common
shares
outstanding
basic
diluted
includes
compensation
follows
research
development
general
administrative
contact
tim
mccarthy
lifesci
advisors
llc
tim
